ArriVent BioPharma (AVBP) Projected to Post Earnings on Monday

ArriVent BioPharma (NASDAQ:AVBP) is projected to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect ArriVent BioPharma to post earnings of ($0.87) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

ArriVent BioPharma Trading Down 0.4%

Shares of AVBP opened at $22.99 on Monday. ArriVent BioPharma has a twelve month low of $15.47 and a twelve month high of $27.85. The firm’s fifty day simple moving average is $21.87 and its 200-day simple moving average is $20.56. The firm has a market capitalization of $949.03 million, a price-to-earnings ratio of -5.42 and a beta of 1.02.

Institutional Investors Weigh In On ArriVent BioPharma

Institutional investors have recently modified their holdings of the company. Infinitum Asset Management LLC raised its holdings in ArriVent BioPharma by 6.6% during the fourth quarter. Infinitum Asset Management LLC now owns 4,123,923 shares of the company’s stock worth $82,973,000 after purchasing an additional 255,000 shares during the last quarter. Suvretta Capital Management LLC increased its position in shares of ArriVent BioPharma by 10.9% in the fourth quarter. Suvretta Capital Management LLC now owns 4,106,035 shares of the company’s stock valued at $82,613,000 after buying an additional 402,583 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of ArriVent BioPharma by 36.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,029,531 shares of the company’s stock worth $37,445,000 after buying an additional 545,991 shares during the last quarter. State Street Corp raised its stake in shares of ArriVent BioPharma by 6.3% during the 4th quarter. State Street Corp now owns 1,091,980 shares of the company’s stock worth $21,971,000 after buying an additional 64,352 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of ArriVent BioPharma by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 753,519 shares of the company’s stock worth $15,164,000 after buying an additional 37,231 shares in the last quarter. Hedge funds and other institutional investors own 9.48% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on AVBP. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a report on Wednesday, January 21st. Cantor Fitzgerald assumed coverage on ArriVent BioPharma in a report on Monday, December 22nd. They issued an “overweight” rating for the company. BTIG Research started coverage on shares of ArriVent BioPharma in a report on Wednesday, December 10th. They set a “buy” rating and a $45.00 price objective on the stock. Citigroup lowered their target price on shares of ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, November 11th. Finally, Truist Financial initiated coverage on shares of ArriVent BioPharma in a research note on Tuesday, November 25th. They set a “buy” rating and a $43.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.